PMID- 22510499
OWN - NLM
STAT- MEDLINE
DCOM- 20120719
LR  - 20211021
IS  - 1746-1596 (Electronic)
IS  - 1746-1596 (Linking)
VI  - 7
DP  - 2012 Apr 17
TI  - Clinicopathological significance of SOX4 expression in primary gallbladder 
      carcinoma.
PG  - 41
LID - 10.1186/1746-1596-7-41 [doi]
AB  - AIM: SOX4, as a member of the SRY-related HMG-box (SOX) transcription factor 
      family, has been demonstrated to be involved in tumorigenesis of many human 
      malignancies; however, its role in primary gallbladder carcinoma (PGC) is still 
      largely unknown. The aim of this study was to investigate SOX4 expression in PGC 
      and its prognostic significance. METHODS: From 1997 to 2006, 136 patients 
      underwent resection for PGC. The median follow-up was 12.8 months. 
      Immunostainings for SOX4 were performed on these archival tissues. The 
      correlation of SOX4 expression with clinicopathological features including 
      survival was analyzed. RESULTS: SOX4 was expressed in 75.0% (102/136) of PGC but 
      not in the normal epithelium of the gallbladder. In addition, the over-expression 
      of SOX4 was significantly associated with low histologic grade (P = 0.02), low 
      pathologic T stage (P = 0.02), and early clinical stage (P = 0.03). The levels of 
      SOX4 immunostainings in PGC tissues with positive nodal metastasis were also 
      significantly lower than those without (P = 0.01). Moreover, Kaplan-Meier curves 
      showed that SOX4 over-expression was significantly related to better overall (P = 
      0.008) and disease-free survival (P = 0.01). Furthermore, multivariate analyses 
      showed that SOX4 expression was an independent risk factor for both overall (P = 
      0.03, hazard ratio, 3.682) and disease-free survival (P = 0.04, hazard ratio, 
      2.215). CONCLUSION: Our data indicate for the first time that the over-expression 
      of SOX4 in PGC was significantly correlated with favorable clinicopathologic 
      features and was an independent prognostic factor for better overall and 
      disease-free survival in patients. Therefore, SOX4 might be an auxiliary 
      parameter for predicting malignant behavior for PGC. VIRTUAL SLIDES: The virtual 
      slide(s) for this article can be found here: 
      http://www.diagnosticpathology.diagnomx.eu/vs/1534825818694957.
FAU - Wang, Chengguo
AU  - Wang C
AD  - Department of general surgery, Tangdu Hospital, Fourth Military Medical 
      University, Xi'an 710038, People's Republic of China.
FAU - Zhao, Huadong
AU  - Zhao H
FAU - Lu, Jianguo
AU  - Lu J
FAU - Yin, Jikai
AU  - Yin J
FAU - Zang, Li
AU  - Zang L
FAU - Song, Nuan
AU  - Song N
FAU - Dong, Rui
AU  - Dong R
FAU - Wu, Tao
AU  - Wu T
FAU - Du, Xilin
AU  - Du X
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120417
PL  - England
TA  - Diagn Pathol
JT  - Diagnostic pathology
JID - 101251558
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (SOX4 protein, human)
RN  - 0 (SOXC Transcription Factors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis
MH  - Disease-Free Survival
MH  - Female
MH  - Gallbladder Neoplasms/*metabolism/mortality/pathology
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Risk Factors
MH  - SOXC Transcription Factors/analysis/*biosynthesis
PMC - PMC3349585
EDAT- 2012/04/19 06:00
MHDA- 2012/07/20 06:00
PMCR- 2012/04/17
CRDT- 2012/04/19 06:00
PHST- 2012/03/14 00:00 [received]
PHST- 2012/04/17 00:00 [accepted]
PHST- 2012/04/19 06:00 [entrez]
PHST- 2012/04/19 06:00 [pubmed]
PHST- 2012/07/20 06:00 [medline]
PHST- 2012/04/17 00:00 [pmc-release]
AID - 1746-1596-7-41 [pii]
AID - 10.1186/1746-1596-7-41 [doi]
PST - epublish
SO  - Diagn Pathol. 2012 Apr 17;7:41. doi: 10.1186/1746-1596-7-41.